Inpharma 1456 - 25 Sep 2004 Olmesartan medoxomil reduces BP, pulse pressure in hypertension Olmesartan medoxomil reduces BP and pulse pressure in patients with hypertension, according to researchers from the US. In their analysis of seven randomised, multicentre trials, 1777 such patients received olmesartan medoxomil 5 (n = 598), 20 (436) or 40 mg/day (195), or placebo, for 6–12 weeks. * The patients who received olmesartan medoxomil had significantly greater reductions in mean systolic BP, diastolic BP and pulse pressure, compared with those who received placebo [see table]. Changes in BP and pulse pressure after treatment with olmesartan medoxomil or placebo Olmesartan Olmesartan Olmesartan Placebo medoxomil medoxomil medoxomil 5 mg/day 20 mg/day 40 mg/day Mean changes (mm Hg) Total population (n = 1777) SBP a –12.4* –15.1* –17.6* –5.6 DBP b –9.8* –12.2* –13.1* –6.2 PP c –1.8 * –2.8* –4.3* 1.2 Patients with a baseline PP of > 55mm Hg(n = 917) SBP –15.1** –17.7* –22* –9.4 DBP –9** –10.8* –12.9* –6.3 PP –5.9** –7.4* –8.8* –2.8 Patients aged ≥ 65 years with a baseline PP of > 55mm Hg (n = 296) SBP –17** –21.8* –22.5* –9.9 DBP –12.8 † –15.1* –15** –8.5 PP –4.2 –6.7* –7.6 † –1.4 * p < 0.001 vs placebo ** p < 0.01 vs placebo † p < 0.03 vs placebo a systolic BP b diastolic BP c pulse pressure Notably, olmesartan medoxomil appeared to be effective in patients with a pulse pressure of > 55mm Hg, even if they were aged ≥ 65 years. * This study was funded by Sankyo Pharma, US, and Forest Laboratories, US. Giles TD, et al. Effects of olmesartan medoxomil on systolic blood pressure and pulse pressure in the management of hypertension. American Journal of Hypertension 17: 690-695, No. 8, Aug 2004 800989073 1 Inpharma 25 Sep 2004 No. 1456 1173-8324/10/1456-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved

Olmesartan medoxomil reduces BP, pulse pressure in hypertension

Download PDF Report

View
213
Download
0

Embed Size (px)

Citation preview

Inpharma 1456 - 25 Sep 2004

Olmesartan medoxomil reducesBP, pulse pressure in hypertension

Olmesartan medoxomil reduces BP and pulsepressure in patients with hypertension, according toresearchers from the US.

In their analysis of seven randomised, multicentretrials, 1777 such patients received olmesartanmedoxomil 5 (n = 598), 20 (436) or 40 mg/day (195), orplacebo, for 6–12 weeks.*

The patients who received olmesartan medoxomilhad significantly greater reductions in mean systolicBP, diastolic BP and pulse pressure, compared withthose who received placebo [see table].

Changes in BP and pulse pressure after treatmentwith olmesartan medoxomil or placebo

Olmesartan Olmesartan Olmesartan Placebomedoxomil medoxomil medoxomil5 mg/day 20 mg/day 40 mg/day

Mean changes (mm Hg)

Total population (n = 1777)SBPa –12.4* –15.1* –17.6* –5.6DBPb –9.8* –12.2* –13.1* –6.2PPc –1.8 * –2.8* –4.3* 1.2Patients with a baseline PP of > 55mm Hg(n = 917)SBP –15.1** –17.7* –22* –9.4DBP –9** –10.8* –12.9* –6.3PP –5.9** –7.4* –8.8* –2.8Patients aged ≥ 65 years with a baseline PP of > 55mm Hg(n = 296)

SBP –17** –21.8* –22.5* –9.9DBP –12.8† –15.1* –15** –8.5PP –4.2 –6.7* –7.6† –1.4* p < 0.001 vs placebo** p < 0.01 vs placebo† p < 0.03 vs placeboa systolic BPb diastolic BPc pulse pressure

Notably, olmesartan medoxomil appeared to beeffective in patients with a pulse pressure of> 55mm Hg, even if they were aged ≥ 65 years.* This study was funded by Sankyo Pharma, US, and ForestLaboratories, US.

Giles TD, et al. Effects of olmesartan medoxomil on systolic blood pressure andpulse pressure in the management of hypertension. American Journal ofHypertension 17: 690-695, No. 8, Aug 2004 800989073